Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics.

Set for release in 2026, the ‘first-of-its-kind’ technology aims to give researchers the ability to analyse more cells in a ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale ...

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

The DNA Sequencing Industry has rapidly transformed into one of the most crucial areas of biotechnology. What was once a time ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

Beijing’s surprise move to blacklist Illumina Inc. has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant.